Under development Stay tuned!

Chronic Kidney Disease (CKD) is one of the common diseases in cats and dogs, especially with age, and older cats and dogs are more likely to develop this disease.

It is important to note that chronic kidney disease (CKD) is different from chronic renal failure (CRF).

CKD refers to renal insufficiency, and most affected dogs and cats present with polyuria and polydipsia, weight loss, vomiting, and poor appetite, focusing on the persistent, irreversible nature of the disease.

There is no clear medical description of the cause of CKD.

CKD is lifelong and irreversible. Treatment aims to minimize the accumulation of toxic metabolites in the blood, maintain adequate hydration, address electrolyte concentration imbalances, ensure proper nutrition, control blood pressure, and slow the progression of kidney disease. There is no guideline therapy for CKD in animals, and the usual treatment facilities can only choose symptomatic treatment.

MT-5106 is an SGLT2 inhibitor, and numerous clinical studies have demonstrated that this class of compounds can improve renal outcomes in patients with diabetes combined with cardiovascular disease or cardiovascular risk factors, with clear renoprotective effects.

In April 2019, MUTIAN co-conducted a large clinical study DAPA-CKD in dogs and cats with chronic kidney disease in 7 countries.This study is an international multicenter randomized double-blind study with 295 affected pets, designed to evaluate the efficacy of MT-5106 in pets with stage 2 to 4 chronic kidney disease and controlled with placebo.

The primary metric observed was deterioration in renal function at the renal composite endpoint, including a ≥50% decrease in glomerular filtration rate, the development of end-stage renal disease (uremia), or death due to cardiovascular disease or renal disease. Due to the overwhelming efficacy (highly significant efficacy) of the results of this study, we terminated the study early. Currently, MT-5106 is in the clinical submission stage and we believe and are certain that the launch of MT-5106 will be a milestone for the treatment of chronic kidney disease in cats and dogs.